Gaush Meditech Inkomsten in het verleden
Verleden criteriumcontroles 3/6
Gaush Meditech has been growing earnings at an average annual rate of 15.2%, while the Medical Equipment industry saw earnings declining at 1.1% annually. Revenues have been declining at an average rate of 2.1% per year. Gaush Meditech's return on equity is 5.7%, and it has net margins of 6.7%.
Belangrijke informatie
15.2%
Groei van de winst
12.4%
Groei van de winst per aandeel
| Medical Equipment Groei van de industrie | 4.3% |
| Inkomstengroei | -2.1% |
| Rendement op eigen vermogen | 5.7% |
| Nettomarge | 6.7% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Gaush Meditech geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 1,348 | 91 | 384 | 62 |
| 31 Mar 24 | 1,377 | 132 | 381 | 57 |
| 31 Dec 23 | 1,406 | 174 | 378 | 53 |
| 30 Sep 23 | 1,391 | -7 | 368 | 49 |
| 30 Jun 23 | 1,377 | -187 | 357 | 45 |
| 31 Mar 23 | 1,315 | -268 | 346 | 43 |
| 31 Dec 22 | 1,254 | -350 | 334 | 41 |
| 30 Sep 22 | 1,276 | -278 | 336 | 39 |
| 30 Jun 22 | 1,298 | -207 | 338 | 37 |
| 31 Mar 22 | 1,298 | -199 | 329 | 30 |
| 31 Dec 21 | 1,298 | -190 | 321 | 24 |
| 31 Dec 20 | 962 | 99 | 251 | 3 |
| 31 Dec 19 | 1,107 | -37 | 279 | 3 |
Kwaliteitswinsten: F7Y has high quality earnings.
Groeiende winstmarge: F7Y became profitable in the past.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: F7Y has become profitable over the past 5 years, growing earnings by 15.2% per year.
Versnelling van de groei: F7Y has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Winst versus industrie: F7Y has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (16.2%).
Rendement op eigen vermogen
Hoge ROE: F7Y's Return on Equity (5.7%) is considered low.